Immune-Mediated Polyarthritis in Dogs: Managing Joint Pain

Immune-mediated polyarthritis causes joint pain and stiffness in dogs, requiring immunosuppressive treatment and careful monitoring to restore quality of life.

Key Facts

IMPA is classified as erosive (joint destruction) or non-erosive (no radiographic changes)
Non-erosive IMPA is more common and responds better to immunosuppressive treatment
Signs include shifting leg lameness, joint swelling, fever, and reluctance to move
Multiple joints are typically affected simultaneously, distinguishing it from infectious or traumatic lameness
Prednisolone at immunosuppressive doses is first-line treatment
Additional immunosuppressants (azathioprine, leflunomide) are added for refractory cases
Underlying triggers including infection, neoplasia, and drug reactions should be investigated and addressed

Welfare Considerations

IMPA causes genuine, significant pain - dogs with polyarthritis are uncomfortable in all four limbs simultaneously, making normal movement and rest painful. The relief provided by appropriate immunosuppressive treatment can be dramatic - dogs often show visible improvement within days of starting prednisolone. Monitoring for treatment adequacy and safe tapering to the lowest effective dose maintains welfare while minimizing drug side effects. Regular reassessment identifies relapse before pain becomes severe.

What You Can Do

Seek veterinary assessment for any dog showing simultaneous multi-joint lameness, especially with fever
Investigate potential underlying triggers before starting treatment - infection and neoplasia must be ruled out
Begin prednisolone at appropriate immunosuppressive doses and monitor response within 1-2 weeks
Taper slowly once remission is achieved - too-rapid reduction risks relapse
Use quality of life assessment to monitor treatment adequacy between veterinary rechecks